4 Result(s)
-
Article
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Here we unif...
-
Article
Open AccessAprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature
Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global...
-
Article
Open AccessDefinitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
Preclinical and clinical studies suggest potential synergy between high dose per fraction focal radiation and immunotherapy. However, conventionally fractionated radiation regimens in combination with concurre...
-
Article
Open AccessEarly mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of pa...
